[Not Yet Scheduled]
VaxNewMo is an early stage biotechnological company developing next-generation conjugate vaccines against infectious diseases using its proprietary bioconjugation technology. Conventionally, conjugate vaccines are manufactured using complex semi-synthetic chemistry to covalently attach polysaccharides to proteins, which is tedious and expensive. To overcome these technical challenges, VaxNewMo has engineered E. coli to recombinantly generate conjugate vaccines in vivo, bypassing the need for chemical conjugation. VaxNewMo owns the only known bioconjugation platform capable of conjugating polysaccharides with glucose at the reducing end to proteins, thereby, enabling the development of the world's first comprehensive pneumococcal bioconjugate vaccine as well as vaccines against many other relevant human pathogens. Currently, our platform technology is being employed to develop bioconjugate vaccines against Streptococcus pneumoniae, Klebsiella pneumoniae, and Group B Streptococcus.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Pneumococcal and Klebsiella bioconjugate vaccines
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
CEO & Co-Founder